Respiratory involvement in systemic lupus erythematosus

Revue des Maladies Respiratoires

Volumn 27, Issue 8, 2010, Pages

  Carmier, D ^a   Marchand Adam, S ^a   Diot, P ^a   Diot, E ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Alveolar haemorrhage; Antiphospholipid syndrome; Lymphoid interstitial pneumonitis; Shrinking lung syndrome; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; GAMMA INTERFERON; INTERLEUKIN 10; PREDNISONE;

ACUTE LUPUS PNEUMONITIS; ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; B LYMPHOCYTE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; GENETIC PREDISPOSITION; HUMAN; HYPOXEMIA; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG DISEASE; LUNG FIBROSIS; LUNG HEMORRHAGE; LUNG LAVAGE; MORBIDITY; PATHOGENESIS; PLASMAPHERESIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SHRINKING LUNG SYNDROME; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VASOSPASM;

EID: 78649654601     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmr.2010.01.003     Document Type: Short Survey

References (115)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Eng J Med 2008;358:929-39.
2. Osler W. On the visceral manifestations of the erythema group of skin diseases. Am J Med Sci 1904;127:1-3.
3. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2007;28:441-50.
4. Mostoslavsky G, Fischel R, Yachimovich N, Yarkoni Y, Rosenmann E, Monestier M, et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur J Immunol 2001;31:1221-7.
5. Isenberg DA, Shoenfeld Y, Walport M, Mackworth-Young C, Dudeney C, Todd-Pokropek A, et al. Detection of crossreactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum 1985;28:999-1007.
6. Rascu A, Repp R, Westerdaal NA, Kalden JR, van de Winkel JG. Clinical relevance of Fc gamma receptor polymorphisms. Ann N Y Acad Sci 1997;815:282-95.
7. Deo YM, Graziano RF, Repp R, van de Winkel JG. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 1997;18:127-35.
8. Seligman VA, Suarez C, Lum R, Inda SE, Lin D, Li H, et al. The Fcgamma receptor IIIA-158F allele is a major risk factor for the development of lupus nephritis among Caucasians but not non-Caucasians. Arthritis Rheum 2001;44:618-25.
9. Johnson KJ, Ward PA. Acute immunologic pulmonary alveolitis. J Clin Invest 1974;54:349-57.
10. Brentjens JR, O'Connell DW, Pawlowski IB, Hsu KC, Andres GA. Experimental immune complex disease of the lung. The pathogenesis of a laboratory model resembling certain human interstitial lung diseases. J Exp Med 1974;140:105-25.
11. Eisenberg H, Simmons DH, Abe C, Chia D, Barnett EV. Immune complex disease in the New Zealand black/white hybrid mouse lung. Chest 1976;69:284-6.
12. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA (Ro) antibodies. J Rheumatol 1989;16:479-81.
13. Mochizuki T, Aotsuka S, Satoh T. Clinical and laboratory features of lupus patients with complicating pulmonary disease. Respir Med 1999;93:95-101.
14. Brentjens J, Ossi E, Albini B, Sepulveda M, Kano K, Sheffer J, et al. Disseminated immune deposits in lupus erythematosus. Arthritis Rheum 1977;20:962-8.
15. Schroeder JO, Euler HH, Loffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 1987;107:344-6.
16. Lee CK, Koh JH, Cha HS, Kim J, Huh W, Chung MP, et al. Pulmonary alveolar hemorrhage in patients with rheumatic diseases in Korea. Scand J Rheumatol 2000;29:288-94.
17. Pertschuk LP, Moccia LF, Rosen Y, Lyons H, Marino CM, Rashford AA, et al. Acute pulmonary complications in systemic lupus erythematosus. Immunofluorescence and light microscopic study. Am J Clin Pathol 1977;68:553-7.
18. Inoue T, Kanayama Y, Ohe A, Kato N, Horiguchi T, Ishii M, et al. Immunopathologic studies of pneumonitis in systemic lupus erythematosus. Ann Intern Med 1979;91:30-4.
19. Churg A, Franklin W, Chan KL, Kopp E, Carrington CB. Pulmonary hemorrhage and immune-complex deposition in the lung. Complications in a patient with systemic lupus erythematosus. Arch Pathol Lab Med 1980;104:388-91.
20. Myers JL, Katzenstein AA. Microangiitis in lupus-induced pulmonary hemorrhage. Am J Clin Pathol 1986;85:552-6.
21. Halla JT, Schrohenloher RE, Volanakis JE. Immune complexes and other laboratory features of pleural effusions: a comparison of rheumatoid arthritis, systemic lupus erythematosus, and other diseases. Ann Intern Med 1980;92:748-52.
22. Hughson MD, He Z, Henegar J, McMurray R. Alveolar hemorrhage and renal microangiopathy in systemic lupus erythematosus. Arch Pathol Lab Med 2001;125:475-83.
23. Marino CT, Pertschuk LP. Pulmonary hemorrhage in systemic lupus erythematosus. Arch Intern Med 1981;141:201-3.
24. D'Cruz D, Khamashta M, Hughes G. Pulmonary manifestations of systemic lupus erythematosus. In: Wallace DJ, Hahn BHH, editors. Dubois' lupus erythematosus. Philadelphia: Lippincott, Williams and Wilkins; 2002. p. 663-83.
25. Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 1981;71:791-8.
26. Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979;119:471-503.
27. Murin S, Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 1998;19:641-65.
28. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995;22:1259-64.
29. Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995;99:624-8.
30. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997;24:309-13.
31. Keane MP, Lynch 3rd JP. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 2000;55:159-66.
32. Ropes MW. Systemic lupus erythematosus. Cambridge, Massachusetts: Harvard University Press; 1976. pp. 33-41.
33. Wang DY, Yang PC, Yu WL, Kuo SH, Hsu NY. Serial antinuclear antibodies titre in pleural and pericardial fluid. Eur Respir J 2000;15:1106-10.
34. Porcel JM, Ordi-Ros J, Esquerda A, Vives M, Madronero AB, Bielsa S, et al. Antinuclear antibody testing in pleural fluid for the diagnosis of lupus pleuretis. Lupus 2007;16:25-7.
35. Crestani B. The respiratory system in connective tissue disorders. Allergy 2005;60:715-34.
36. McKnight KM, Adair NE, Agudelo CA. Successful use of tetracycline pleurodesis to treat massive pleural effusion secondary to systemic lupus erythematosus. Arthritis Rheum 1991;34:1483-4.
37. Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol 1996;166:301-7.
38. Eichacker PQ, Pinsker K, Epstein A, Schiffenbauer J, Grayzel A. Serial pulmonary function testing in patients with systemic lupus erythematosus. Chest 1988;94:129-32.
39. Miller LR, Greenberg SD, McLarty JW. Lupus lung. Chest 1985;88:265-9.
40. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
41. Hedgpeth MT, Boulware DW. Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti-Ro (SS-A) antibodies. Arthritis Rheum 1988;31:545-8.
42. Cha SI, Fessler MB, Cool CD, Schwarz MI, Brown KK. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006;28:364-9.
43. Orens JB, Martinez FJ, Lynch 3rd JP. Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1994;20:159-93.
44. Cordier JF, Loire R, Peyrol S. Bronchiolitis obliterans organizing pneumonia (BOOP). Characteristics and boundaries of an anatomo-clinical entity. Rev Mal Respir 1991;8:139-52.
45. Gammon RB, Bridges TA, Al-Nezir H, Alexander CB, Kennedy Jr JI. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus. Chest 1992;102:1171-4.
46. Takada H, Saito Y, Nomura A, Ohga S, Kuwano K, Nakashima N, et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in systemic lupus erythematosus. Pediatr Pulmonol 2005;40:257-60.
47. Matthay RA, Schwarz MI, Petty TL, Stanford RE, Gupta RC, Sahn SA, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975;54:397-409.
48. Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997;23:841-53.
49. Smith GA, Ward PH, Berci G. Laryngeal lupus erythematosus. J Laryngol Otol 1978;92:67-73.
50. Teitel AD, MacKenzie CR, Stern R, Paget SA. Laryngeal involvement in systemic lupus erythematosus. Semin Arthritis Rheum 1992;22:203-14.
51. Scarpelli DG, Mc CF, Scott JK. Acute lupus erythematosus with laryngeal involvement. N Engl J Med 1959;261:691-4.
52. Toomey JM, Snyder 3rd GG, Maenza RM, Rothfield NF. Acute epiglottitis due to systemic lupus erythematosus. Laryngoscope 1974;84:522-7.
53. Curley JW, Byron MA, Bates GJ. Crico-arytenoid joint involvement in acute systemic lupus erythematosus. J Laryngol Otol 1986;100:727-32.
54. Nossent JC, Berend K. Cricoarytenoiditis in systemic lupus erythematosus. Scand J Rheumatol 1998;27:237-8.
55. Wohlgelernter D, Loke J, Matthay RA, Siegel NJ. Systemic and discoid lupus erythematosus: analysis of pulmonary function. Yale J Biol Med 1978;51:157-64.
56. Andonopoulos AP, Constantopoulos SH, Galanopoulou V, Drosos AA, Acritidis NC, Moutsopoulos HM. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest 1988;94:312-5.
57. Silberstein SL, Barland P, Grayzel AI, Koerner SK. Pulmonary dysfunction in systemic lupus erythematosus: prevalence classification and correlation with other organ involvement. J Rheumatol 1980;7:187-95.
58. Rolla G, Brussino l, Bertero MT, Bucca C, Converso M, Caligaris-Cappio F. Respiratory function in systemic lupus erythematosus: relation with and severity. Lupus 1996;5:38-43.
59. Kinney WW, Angelillo VA. Bronchiolitis in systemic lupus erythematosus. Chest 1982;82:646-9.
60. Godeau B, Cormier C, Menkes CJ. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Ann Rheum Dis 1991;50:956-8.
61. Venizelos PC, Al-Bazzaz F. Pulmonary function abnormalities in systemic lupus erythematosus responsive to glucocorticoid therapy. Chest 1981;79:702-4.
62. Weber F, Prior C, Kowald E, Schmuth M, Sepp N. Cyclophosphamide therapy is effective for bronchiolitis obliterans occurring as a late manifestation of lupus erythematosus. Br J Dermatol 2000;143:453-5.
63. Bankier AA, Kiener HP, Wiesmayr MN, Fleischmann D, Kontrus M, Herold CJ, et al. Discrete lung involvement in systemic lupus erythematosus: CT assessment. Radiology 1995;196:835-40.
64. Ooi GC, Ngan H, Peh WC, Mok MY, Ip M. Systemic lupus erythematosus patients with respiratory symptoms: the value of HRCT. Clin Radiol 1997;52:775-81.
65. Johnson SR, Gladman DD, Urowitz MB, Ibanez D, Granton JT. Pulmonary hypertension in systemic lupus. Lupus 2004;13:506-9.
66. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national register. Am J Respir Crit Care Med 2006;173:1023-30.
67. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000;9:338-42.
68. Cottin V. Hypertension artérielle pulmonaire associée aux connectivites. Rev Mal Respir 2006;23: S61-72.
69. Cherin P, Delfraissy JF, Bletry O, Dormont J, Godeau P. Les manifestations pleuro-pulmonaires du lupus érythémateux systémique. Rev Med Interne 1991;12:355-62.
70. Mouthon L, Guillevin L, Humbert M. Pulmonary arterial hypertension: an autoimmune disease? Eur Respir J 2005;26:986-8. (Pubitemid 41829926)
71. Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 2006;25:866-72.
72. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-63.
73. Yoshio T, Masuyama J, Sumiya M, Minota S, Kano S. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1994;21:2058-63.
74. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
75. Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 1999;26:1923-9.
76. Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999;54:273-7.
77. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006;130:182-9.
78. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002;29:282-7.
79. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. (Pubitemid 41653106)
80. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
81. Heresi GA, Minai OA. Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy. Respir Med 2007;101:2099-107.
82. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000;117:14-8.
83. Abramson SB, Dobro J, Eberle MA, Benton M, Reibman J, Epstein H, et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 1991;114:941-7.
84. Martinez-Taboada VM, Blanco R, Armona J, Fernandez-Sueiro JL, Rodriguez-Valverde V. Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity? Lupus 1995;4:259-62.
85. Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 1994;37:376-83.
86. King JT. Connective tissue disease. In: King JT, Schwarz MI, editors. Interstitial lung disease. London: BC Decker; 1998. p. 451-506.
87. Schwab EP, Schumacher Jr HR, Freundlich B, Callegari PE. Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 1993;23:8-15. (Pubitemid 23270889)
88. Liu MF, Lee JH, Weng TH, Lee YY. Clinical experience of 13cases with severe pulmonary hemorrhage in systemic lupus erythematosus with active nephritis. Scand J Rheumatol 1998;27:291-5.
89. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997;76:192-202.
90. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000;118:1083-90.
91. Keane MP, Van De Ven CJ, Lynch 3rd JP, McCune WJ. Systemic lupus during pregnancy with refractory alveolar haemorrhage: recovery following termination of pregnancy. Lupus 1997;6:730-3.
92. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
93. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: a meta-analysis. Lupus 1997;6:467-73.
94. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993;72:113-24.
95. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239-43.
96. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:1050-7.
97. Bertolaccini ML, Khamashta MA. Laboratory diagnosis and management challenges in the antiphospholipid syndrome. Lupus 2006;15:172-8.
98. Swigris JJ, Fischer A, Gillis J, Meehan RT, Brown KK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 2008;133:271-80.
99. Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 2006;5:344-8.
100. Asherson RA, Piette JC. The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus 1996;5:414-7.
101. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50patients. Medicine (Baltimore) 1998;77:195-207.
102. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-4.
103. Branger S, Schleinitz N, Gayet S, Veit V, Kaplanski G, Badier M, et al. Le syndrome des poumons rétractés et les maladies immunes. Rev Med Interne 2004;25:83-90.
104. Laroche CM, Mulvey DA, Hawkins PN, Walport MJ, Strickland B, Moxham J, et al. Diaphragm strength in the shrinking lung syndrome of systemic lupus erythematosus. Q J Med 1989;71:429-39.
105. Soubrier M, Dubost JJ, Piette JC, Urosevic Z, Rami S, Oualid T, et al. Shrinking lung syndrome in systemic lupus erythematosus. A report of three cases. Rev Rhum Engl Ed 1995;62:395-8.
106. Ishii M, Uda H, Yamagami T, Katada Y. Possible association of "shrinking lung" and anti-Ro/SSA antibody. Arthritis Rheum 2000;43:2612-3.
107. Allen D, Stoller JK, Minai OA. A 45-year-old woman with systemic lupus erythematosus and progressive dyspnea. Chest 2007;131:1252-5.
108. Gibson GJ, Edmonds JP, Hughes GR. Diaphragm function and lung involvement in systemic lupus erythematosus. Am J Med 1977;63:926-32.
109. Rubin LA, Urowitz MB. Shrinking lung syndrome in SLE: a clinical pathologic study. J Rheumatol 1983;10:973-6.
110. Hardy K, Herry I, Attali V, Cadranel J, Similowski T. Bilateral phrenic paralysis in a patient with systemic lupus erythematosus. Chest 2001;119:1274-7.
111. Mills GH, Kyroussis D, Hamnegard CH, Wragg S, Polkey MI, Moxham J, et al. Cervical magnetic stimulation of the phrenic nerves in bilateral diaphragm paralysis. Am J Respir Crit Care Med 1997;155:1565-9. (Pubitemid 27216659)
112. Mador MJ, Khan S, Kufel TJ. Bilateral anterolateral magnetic stimulation of the phrenic nerves can detect diaphragmatic fatigue. Chest 2002;121:452-8.
113. Hawkins P, Davidson AG, Dasgupta B, Moxham J. Diaphragm strength in acute systemic lupus erythematosus in patients with paradoxical abdominal motion and reduced lung volumes. Thorax 2001;56:329-30.
114. Warrington KJ, Moder KG, Brutinel WM. The shrinking lungs syndrome in systemic lupus erythematosus. Mayo Clin Proc 2000;75:467-72.
115. Karim MY, Miranda LC, Tench CM, Gordon PA, D'Cruz DP, Khamashta MA, et al. Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum 2002;31:289-98.